Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies.
Immunological properties of melanoma TILs before and/or after IL-2-based biotherapies were investigated. TILs harvested before therapies, including those for adoptive transfer, proliferated well in culture with IL-2 and displayed cytotoxicity relatively restricted to autologous tumor cells. In contrast, TILs during or at the end of IL-2 based therapies did not proliferate in culture with IL-2. TILs from tumors even harvested 45 days after the end of IL-2 therapy modestly proliferated in culture with IL-2 and showed MHC-nonrestricted cytotoxicity. The number of live tumor cells that were yielded from melanomas during or at the end of IL-2-based therapies significantly decreased in all nine patients with metastatic melanomas, regardless of their clinical responses (2 PR, 2 MR, 2 SD, and 3 PD). Collectively, these results suggest that current IL-2-based therapies resulted in both transient nonresponsiveness of TILs to IL-2 and transient decrease in the number of live tumour cells in most melanoma patients.
Itoh
K
K
Department of Immunology, University of Texas M.D. Anderson Cancer Center, Houston.
Balch
C M
CM
Murray
J L
JL
Parkinson
D R
DR
Markowitz
A B
AB
Talpaz
M
M
Lee
K
K
Zukiwski
A A
AA
Ross
M I
MI
Legha
S S
SS
D002452:Cell Count; D002478:Cells, Cultured; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008545:Melanoma / Q000556:secondary / Q000628:therapy*; D013997:Time Factors
D007376:Interleukin-2